Shao-Yang Wang1, Wei Chen1, Wei Xu1, Jie-Qiong Li1, Xiao-He Hou1, Ya-Nan Ou1, Jin-Tai Yu2, Lan Tan1. 1. Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. 2. Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Abstract
BACKGROUND: Neurofilament light chain (NFL) as a potential biomarker of neurodegenerative diseases has been studied in a number of studies. Thus, a comprehensive meta-analysis is warranted to assess NFL performance in neurodegenerative diseases. OBJECTIVE: To assess the performance of NFL in blood and cerebrospinal fluid (CSF) as a biomarker for neurodegenerative diseases. METHODS: A total of 36 studies with comparison of NFL level between individuals with neurodegenerative diseases and controls were retrieved from PubMed, Web of Science and Science Direct, and the ratio of means method and delta method based on the random-effect model were used to analyze the differentiation of NFL between patients and controls. RESULTS: Differentiation of CSF NFL between patients with neurodegenerative diseases and controls showed significant results. Although a few studies on blood NFL available were included in the meta-analysis, the results still showed a distinct possibility that NFL could be a potential biomarker for neurodegenerative diseases. NFL levels were increased significantly in dementias, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, and Huntington's disease. By contrast, NFL levels were not increased in Parkinson's disease (PD), although they were increased significantly in PD-related disorders (multiple system atrophy and progressive supranuclear palsy). CONCLUSIONS: In our study, in addition to PD, NFL was suggested to be a global diagnostic biomarker for neurodegenerative diseases. Moreover, it could be used in differential diagnosis of PD and PD-related disorders. However, it was worth noting that NFL was not appropriate for diagnosis or differential diagnosis without clinical symptoms and other auxiliary examinations.
BACKGROUND: Neurofilament light chain (NFL) as a potential biomarker of neurodegenerative diseases has been studied in a number of studies. Thus, a comprehensive meta-analysis is warranted to assess NFL performance in neurodegenerative diseases. OBJECTIVE: To assess the performance of NFL in blood and cerebrospinal fluid (CSF) as a biomarker for neurodegenerative diseases. METHODS: A total of 36 studies with comparison of NFL level between individuals with neurodegenerative diseases and controls were retrieved from PubMed, Web of Science and Science Direct, and the ratio of means method and delta method based on the random-effect model were used to analyze the differentiation of NFL between patients and controls. RESULTS: Differentiation of CSF NFL between patients with neurodegenerative diseases and controls showed significant results. Although a few studies on blood NFL available were included in the meta-analysis, the results still showed a distinct possibility that NFL could be a potential biomarker for neurodegenerative diseases. NFL levels were increased significantly in dementias, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, and Huntington's disease. By contrast, NFL levels were not increased in Parkinson's disease (PD), although they were increased significantly in PD-related disorders (multiple system atrophy and progressive supranuclear palsy). CONCLUSIONS: In our study, in addition to PD, NFL was suggested to be a global diagnostic biomarker for neurodegenerative diseases. Moreover, it could be used in differential diagnosis of PD and PD-related disorders. However, it was worth noting that NFL was not appropriate for diagnosis or differential diagnosis without clinical symptoms and other auxiliary examinations.
Authors: Wolfgang Singer; Ann M Schmeichel; Mohammad Shahnawaz; James D Schmelzer; Bradley F Boeve; David M Sletten; Tonette L Gehrking; Jade A Gehrking; Anita D Olson; Rodolfo Savica; Mariana D Suarez; Claudio Soto; Phillip A Low Journal: Ann Neurol Date: 2020-08-01 Impact factor: 10.422
Authors: Whitley W Aamodt; Teresa Waligorska; Junchao Shen; Thomas F Tropea; Andrew Siderowf; Daniel Weintraub; Murray Grossman; David Irwin; David A Wolk; Sharon X Xie; John Q Trojanowski; Leslie M Shaw; Alice S Chen-Plotkin Journal: Mov Disord Date: 2021-09-04 Impact factor: 10.338
Authors: Kelly Virecoulon Giudici; Sophie Guyonnet; John E Morley; Andrew D Nguyen; Geetika Aggarwal; Angelo Parini; Yan Li; Randall J Bateman; Bruno Vellas; Philipe de Souto Barreto Journal: J Gerontol A Biol Sci Med Sci Date: 2022-06-01 Impact factor: 6.591
Authors: Wolfgang Singer; Ann M Schmeichel; Mohammad Shahnawaz; James D Schmelzer; David M Sletten; Tonette L Gehrking; Jade A Gehrking; Anita D Olson; Mariana D Suarez; Pinaki P Misra; Claudio Soto; Phillip A Low Journal: Ann Neurol Date: 2021-04-30 Impact factor: 11.274
Authors: Breton M Asken; Lawren VandeVrede; Julio C Rojas; Corrina Fonseca; Adam M Staffaroni; Fanny M Elahi; Cutter A Lindbergh; Alexandra C Apple; Michelle You; Sophia Weiner-Light; Nivetha Brathaban; Nicole Fernandes; Adam L Boxer; Bruce L Miller; Howie J Rosen; Joel H Kramer; Kaitlin B Casaletto Journal: J Int Neuropsychol Soc Date: 2021-06-22 Impact factor: 3.114
Authors: Breton M Asken; Fanny M Elahi; Renaud La Joie; Amelia Strom; Adam M Staffaroni; Cutter A Lindbergh; Alexandra C Apple; Michelle You; Sophia Weiner-Light; Nivetha Brathaban; Nicole Fernandes; Anna Karydas; Paul Wang; Julio C Rojas; Adam L Boxer; Bruce L Miller; Gil D Rabinovici; Joel H Kramer; Kaitlin B Casaletto Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.160